Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors
Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota...
Main Authors: | Romain Daillère, Bertrand Routy, Anne-Gaëlle Goubet, Alexandria Cogdill, Gladys Ferrere, Carolina Alves-Costa Silva, Aurélie Fluckiger, Pierre Ly, Yacine Haddad, Eugenie Pizzato, Cassandra Thelemaque, Marine Fidelle, Marine Mazzenga, Maria Paula Roberti, Cléa Melenotte, Peng Liu, Safae Terrisse, Oliver Kepp, Guido Kroemer, Laurence Zitvogel, Lisa Derosa |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1794423 |
Similar Items
-
Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
by: Marine Fidelle, et al.
Published: (2020-12-01) -
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
by: Mariona Cabo, et al.
Published: (2017-12-01) -
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
by: Lisa Derosa, et al.
Published: (2018-06-01) -
COVID-19: a challenge for oncology services
by: Bertrand Routy, et al.
Published: (2020-01-01) -
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
by: Gladys Ferrere, et al.
Published: (2021-01-01)